Masayuki Hagiwara (Eiji Kikuchi)

Years Active: 2018-2019
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Koichiro Ogihara, Takeo Kosaka, Shogo Okazaki, Masayuki Hagiwara, Toshikazu Takeda, Kazuhiro Matsumoto, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, Mototsugu Oya
Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Cancer science 110 (4) (2019)
Masayuki Hagiwara, Masayuki Hagiwara, Nobuyuki Tanaka, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, Mototsugu Oya
Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. BMC cancer 18 (1) (2018)
Nobuyuki Tanaka, Shintaro Katayama, Aparna Reddy, Kaneyasu Nishimura, Naoya Niwa, Hiroshi Hongo, Koichiro Ogihara, Takeo Kosaka, Ryuichi Mizuno, Masayuki Hagiwara, Shuji Mikami, Ayako Miyakawa, Ernest Arenas, Juha Kere, Mototsugu Oya, Per Uhlen
Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63. Cancer medicine 7 (12) (2018)

Masayuki Hagiwara.css-eqlu8i{font-size:small;padding-left:4px;} (Eiji Kikuchi)